Dianthus Therapeutics (NASDAQ:DNTH) Trading Down 6% – Should You Sell?

Dianthus Therapeutics, Inc. (NASDAQ:DNTH)’s stock price traded down 6% during trading on Tuesday . The company traded as low as $24.01 and last traded at $24.16. 31,783 shares traded hands during trading, a decline of 85% from the average session volume of 205,803 shares. The stock had previously closed at $25.70.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on the stock. Wedbush decreased their price target on shares of Dianthus Therapeutics from $38.00 to $36.00 and set an “outperform” rating on the stock in a research note on Friday, August 9th. Raymond James boosted their price target on shares of Dianthus Therapeutics from $51.00 to $56.00 and gave the stock an “outperform” rating in a research note on Friday, November 8th. Oppenheimer boosted their target price on Dianthus Therapeutics from $48.00 to $52.00 and gave the stock an “outperform” rating in a research report on Monday, November 11th. Finally, HC Wainwright reissued a “buy” rating and set a $40.00 price objective on shares of Dianthus Therapeutics in a research report on Monday, November 11th. Eight equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, Dianthus Therapeutics presently has an average rating of “Buy” and a consensus target price of $46.43.

Dianthus Therapeutics Stock Down 0.9 %

The firm has a market capitalization of $753.62 million, a PE ratio of -9.66 and a beta of 1.75. The stock’s fifty day simple moving average is $26.65 and its 200 day simple moving average is $26.53.

Dianthus Therapeutics (NASDAQ:DNTH) last released its earnings results on Thursday, November 7th. The company reported ($0.74) EPS for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.15). Dianthus Therapeutics had a negative return on equity of 21.68% and a negative net margin of 1,250.32%. The company had revenue of $2.17 million for the quarter, compared to analysts’ expectations of $1.07 million. On average, analysts predict that Dianthus Therapeutics, Inc. will post -2.61 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of DNTH. State Street Corp increased its position in shares of Dianthus Therapeutics by 101.4% in the third quarter. State Street Corp now owns 821,131 shares of the company’s stock worth $22,483,000 after purchasing an additional 413,425 shares during the period. Vanguard Group Inc. grew its position in shares of Dianthus Therapeutics by 250.0% during the 1st quarter. Vanguard Group Inc. now owns 537,828 shares of the company’s stock valued at $16,135,000 after acquiring an additional 384,182 shares during the period. Janus Henderson Group PLC increased its position in shares of Dianthus Therapeutics by 40.5% during the third quarter. Janus Henderson Group PLC now owns 949,334 shares of the company’s stock worth $25,936,000 after acquiring an additional 273,670 shares during the period. Point72 Asset Management L.P. raised its stake in shares of Dianthus Therapeutics by 151.3% during the 3rd quarter. Point72 Asset Management L.P. now owns 437,700 shares of the company’s stock worth $11,984,000 after buying an additional 263,500 shares during the last quarter. Finally, Great Point Partners LLC lifted its holdings in shares of Dianthus Therapeutics by 21.3% in the second quarter. Great Point Partners LLC now owns 757,929 shares of the company’s stock valued at $19,615,000 after purchasing an additional 132,929 shares in the last quarter. Institutional investors and hedge funds own 47.53% of the company’s stock.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.